Materias dentro de su búsqueda.
Mostrando 2,021 - 2,040 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.69s Limitar resultados
  1. 2021
    “…In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
  2. 2022
    “…PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER(+)/HER2(−) breast cancer; and (ii) the pharmacodynamic effect of the agents on the biomarkers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
  3. 2023
    “…RESULTS: The conversion rate of anyone receptor (ER, PR, or HER2) between the primary lesions and brain metastatic lesions was 45.0% (18/40), of which the ER inconsistency rate was 25.0%, the PR inconsistency rate was 22.5%, and the HER-2 inconsistency rate was 15.0%, and the receptor conversion resulted in a subtype conversion of 27.5% (11/40). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
  4. 2024
    “…SIMPLE SUMMARY: Breast cancer is the most diagnosed malignancy in woman worldwide and, despite the availability of new innovative therapies, it remains the first cause of death for tumor in woman. 20% of all breast cancer cases are HER2 positive, meaning that they are characterized by an aberrant expression of the growth factor receptor HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
  5. 2025
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
  6. 2026
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Relation between the Dam’s Weight on Superficial Temperature of Her Puppies at Different Stages of the Post-Partum
  7. 2027
    “…The prognosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) remained unsatisfactory currently, more anti-HER2 agents are needed. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
  8. 2028
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Microscopic Diffusion of Atomic Hydrogen and Water in HER Catalyst MoS(2) Revealed by Neutron Scattering
  9. 2029
    por Alasmari, Moudi M.
    Publicado 2022
    “…SIMPLE SUMMARY: HER2+ metastatic breast cancer (MBC) is a highly prevalent type of breast cancer owing to its resistance to conventional anti-HER2 drugs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
  10. 2030
    “…Among them, the Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target. With the continuous optimization of chemotherapeutic drugs and chemotherapy regimens, the prognosis of some HER2-positive GC patients has been greatly improved. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
  11. 2031
    “…It was found that the co-expression of EGFR and HER2 was associated with a worse prognosis. Therefore, we generated EGFR-positive BLBC cells with stable HER2 overexpression and analyzed the profile of secretory cytokines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
  12. 2032
    “…Inoculation of CMT-1 cells induced a complex HER2-enriched mammary tumor with metastasis in mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line
  13. 2033
    “…Median follow-up was 36.18 months (95% CI 30.19-42.66). HER2 status was available in 62 cases (84%) and in 42% the protein was overexpressed (HER2+). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
  14. 2034
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “It Was All Wrong and Shameful to Beat Her”: Discursive Analysis of Men’s Talk of Intimate Partner Violence
  15. 2035
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
  16. 2036
    “…METHODS: In this study, we retrospectively reviewed the data of 1603 patients who were diagnosed with HER2‐negative breast invasive ductal carcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
  17. 2037
    “…Heart failure (HF) risks from other anti-HER2 therapies are less clear. OBJECTIVES: Using World Health Organization pharmacovigilance data, the authors compared HF odds across anti-HER2 regimens. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer
  18. 2038
    “…BACKGROUND: The emergence of HER2 antibody-drug conjugates provides new treatment decisions for breast cancer patients, especially those with HER2-low expression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
  19. 2039
    “…HER2-positive breast cancer patients carrying the germline TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) are resistant to anti-HER2 therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer
  20. 2040
    “…Herein, we sought to determine the feasibility and safety of neratinib and trametinib in patients with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation and KRAS mutation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Herramientas de búsqueda: RSS